Press Releases

Date Title and Summary View
Toggle Summary Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™
Technical Transfer of manufacturing process to CMO signals commencement of commercial readiness activities NDA planned for Q4 2019 FREMONT, Calif. , June 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has
View HTML
Toggle Summary Zosano Pharma Reports First Quarter 2019 Financial Results
Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology Conference call scheduled for 1:30 pm PT today FREMONT, Calif.
View HTML
Toggle Summary Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
FREMONT, Calif. , May 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update
FREMONT, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and
View HTML
Toggle Summary Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain
FREMONT, Calif. , April 16, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed trials using newly FDA -recommended
View HTML
Toggle Summary Zosano Announces Pricing of Public Offering of Common Stock
FREMONT, Calif. , April 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million , before deducting underwriting discounts
View HTML
Toggle Summary Zosano Pharma Announces Proposed Public Offering of Common Stock
FREMONT, Calif. , April 08, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered
View HTML
Toggle Summary Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results
FREMONT, Calif. --(BUSINESS WIRE)--Mar. 14, 2019-- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018 , as well as recent business highlights.
View HTML
Toggle Summary Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference
FREMONT, Calif. , March 11, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will participate in a panel titled “Drug Delivery” to be held on Monday,
View HTML
Toggle Summary Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update
FREMONT, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Thursday, March 14, 2019 at 4:30 p.m. ET to discuss financial results for the fourth quarter
View HTML